[7–9] In addition, treatment beyond progression of EGFR-MT NSCLC with an EGFR-TKI has been associated with improved overall survival, compared to those in whom the TKI was permanently discontinued. This evidence concerns the gene EGFR and non-small cell lung carcinoma.